News

Amvuttra (vutrisiran) appears to be safe for long-term use in adults with familial amyloid polyneuropathy (FAP) and those with another form of transthyretin amyloidosis (ATTR) that causes heart damage. That’s according to an analysis of more than 700 patients who received Amvuttra in one of two Phase 3…

A single dose of gene-editing therapy nexiguran ziclumeran (nex-z) leads to deep reductions in blood levels of the disease-causing transthyretin (TTR) protein in adults with familial amyloid polyneuropathy for up to three years. That’s according to longer-term data from a Phase 1 clinical trial (NCT04601051). The trial also…

Yoltech Therapeutics has raised about $45 million in funding to advance its clinical programs, including YOLT-201, an experimental gene-editing therapy for familial amyloid polyneuropathy (FAP) and other forms of transthyretin amyloidosis (ATTR). YOLT-201 is being tested in a Phase 1/2a clinical trial (NCT06539208) that is still recruiting…

There is a high prevalence of the Val30Met (V30M) TTR gene mutation — the most common mutation associated with familial amyloid polyneuropathy (FAP) and other forms of hereditary transthyretin amyloidosis (ATTRv) — in Spain’s Balearic Islands, according to a new report by scientists in the region. The scientists believe…

Hereditary transthyretin amyloidosis (ATTRv), a group of diseases that includes familial amyloid polyneuropathy (FAP), might not be as easily categorized into distinct neurological and heart-related disease subtypes as once thought, according to a study. FAP has long been considered the neurological form of ATTRv, while ATTR amyloidosis with cardiomyopathy…

Specialists in Scandinavia have updated the Kumamoto scale, a tool long used to monitor the progression of hereditary transthyretin amyloidosis (ATTRv), a group of diseases that includes familial amyloid polyneuropathy (FAP). The revised scale introduces clearer definitions and more precise scoring for symptoms and organ involvement, while still being practical…

People with early-stage familial amyloid polyneuropathy (FAP) cost society more than twice as much as symptom-free carriers of disease-causing genetic mutations, largely due to higher medical needs and lost productivity at work, according to a study in Spain. “Not only early-stage [FAP] patients, but also asymptomatic carriers, are generating…

Early genetic screening for people with unexplained nerve damage, or neuropathy, may help uncover undiagnosed cases of familial amyloid polyneuropathy (FAP), allowing faster access to treatment. In a study from France, 1% of 400 adults with neuropathy of unknown origin were found to have a FAP-causing mutation, even…

A Phase 3 clinical trial testing Intellia Therapeutics’ gene-editing therapy nexiguran ziclumeran (nex-z) in adults with familial amyloid neuropathy (FAP) is ahead of its planned enrollment schedule, with recruitment now expected to be completed in the first half of 2026. That’s according to a press release from…

Using a small sample of tissue from skin — obtained via a skin biopsy — can help diagnose familial amyloid polyneuropathy (FAP) early by looking for the presence of disease-causing toxic amyloid deposits and measuring the number of small nerve fibers in the outermost layer of a person’s skin.